Blonanserin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Blonanserin: From Schizophrenia to retinal dystrophy with or without extraocular anomalies
One-Sentence Summary
Blonanserin is an atypical antipsychotic originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Schizophrenia |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (18 of 18) – CDSCO approval status is not included in this data |
| Number of Listed Products | 18 (valid: 18) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, blonanserin is a dopamine D2/D3 and serotonin 5-HT2A receptor antagonist. Its efficacy in schizophrenia is established, and it is approved for that use in Japan. The pharmacology data compiled for this report confirm binding to the 5-HT2A receptor (HTR2A) and the D2 receptor (DRD2).
No mechanistic link to retinal dystrophy is supported by the available data. No retinal target or pathway connection has been documented, and the original mechanism of action record is incomplete. The high TxGNN score (0.9998) is a computational prediction only. It has no clinical or literature corroboration, so it should be treated as a hypothesis-generating signal rather than a rational basis for treatment.
Other top-ranked predictions are similarly unsupported. They include congenital disorder of glycosylation with defective fucosylation, Charcot-Marie-Tooth disease type 1G, hydranencephaly, a polymicrogyria syndrome, several myopia subtypes, and atypical glycine encephalopathy. All have scores of about 99.96–0.9997 and no trials or publications. For the myopia entries, retinal dopamine signalling is loosely associated with eye growth regulation, but the direction of effect for a D2 antagonist is uncertain and could be unfavourable.
India Market Information
18 valid single-ingredient registrations were found, all oral tablets. None of the records include approved indication text. The main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 32559 | Blonet 2mg Tablet (Shatayushi Healthcare) | Strip of 10 tablets | Not stated |
| 72896 | Elicia 4 Tablet (Zydus Cadila) | Strip of 10 tablets | Not stated |
| 73328 | Elicia 8 Tablet (Zydus Cadila) | Strip of 10 tablets | Not stated |
| 26704 | Blonitas 8 Tablet (Intas Pharmaceuticals) | Strip of 10 tablets | Not stated |
| 33159 | Blosana 4 Tablet (Ryon Pharma) | Strip of 10 tablets | Not stated |
Safety Considerations
Please refer to the package insert for safety information.
The only interaction-related data compiled are receptor-level pharmacology records (5-HT2A and D2 receptor binding), not drug-drug interactions. No contraindication edges were found in the knowledge graph.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score. There are no clinical trials, no literature, and no plausible mechanistic link between D2/5-HT2A antagonism and retinal dystrophy. Evidence is at the lowest level (L5).
To proceed, the following is needed:
- Detailed mechanism of action data, and any evidence of retinal or ocular targets
- Package insert warnings and contraindications from the India regulatory source, since safety screening cannot proceed without them
- Preclinical studies (for example, retinal degeneration models) to test the hypothesis
- A literature and trial search for the predicted indication
- Assessment of whether an oral antipsychotic is a suitable route and risk profile for a chronic inherited retinal condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.